NRx Pharmaceuticals Signed License Data And Technical Information Agreement With Columbia University For Rights To Data From Randomized, Active-Controlled Trial Of 80 Patients Hospitalized For Acute Suicidality In Depression
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals has entered into an agreement with Columbia University for the rights to data from a trial on the effectiveness of Ketamine in treating acute suicidality in depression. The trial showed Ketamine to be highly effective, and NRx plans to use this data to support a New Drug Application to the FDA in Q1 2024.
December 19, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRx Pharmaceuticals has licensed data from Columbia University on a trial showing Ketamine's effectiveness in treating suicidality, aiming to support a New Drug Application in early 2024.
The licensing agreement with Columbia University provides NRx Pharmaceuticals with compelling data that could significantly support their upcoming New Drug Application to the FDA. This positive development is likely to be viewed favorably by investors, potentially leading to a short-term increase in NRXP's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100